ORAL RU 28965 IN RESPIRATORY INFECTIONS

We carried out a study on the clinical efficacy and safety of RU 28965. In total, eleven patients with respiratory infections (pneuthonia 4, bronchiectasis 4, acute bronchitis 2, and chronic bronchitis 1) were treated with oral RU 28965 in a daily dose of 300-400 mg for 4-24 days. Clinical efficacy...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 36; no. Supplement4; pp. 306 - 310
Main Authors SATOH, TOSHINOBU, KUDO, KOICHIRO, KABE, JUNZABURO, YOSHIMOTO, KEIKO, KOWADA, AKIKO
Format Journal Article
LanguageEnglish
Japanese
Published Japanese Society of Chemotherapy 1988
公益社団法人 日本化学療法学会
Online AccessGet full text
ISSN0009-3165
1884-5894
DOI10.11250/chemotherapy1953.36.Supplement4_306

Cover

Abstract We carried out a study on the clinical efficacy and safety of RU 28965. In total, eleven patients with respiratory infections (pneuthonia 4, bronchiectasis 4, acute bronchitis 2, and chronic bronchitis 1) were treated with oral RU 28965 in a daily dose of 300-400 mg for 4-24 days. Clinical efficacy was good in 5 cases, fair in 5 and poor in 1, with an overall clinical efficacy rate of 45.5%. Four strains of H. influenzae were isolated from sputum. Two strains were eradicated and the rest were unchanged after the treatment. Neither clinical side-effects nor abnormal laboratory findings were observed.
AbstractList We carried out a study on the clinical efficacy and safety of RU 28965. In total, eleven patients with respiratory infections (pneuthonia 4, bronchiectasis 4, acute bronchitis 2, and chronic bronchitis 1) were treated with oral RU 28965 in a daily dose of 300-400 mg for 4-24 days. Clinical efficacy was good in 5 cases, fair in 5 and poor in 1, with an overall clinical efficacy rate of 45.5%. Four strains of H. influenzae were isolated from sputum. Two strains were eradicated and the rest were unchanged after the treatment. Neither clinical side-effects nor abnormal laboratory findings were observed.
We carried out a study on the clinical efficacy and safety of RU 28965. In total, eleven patients with respiratory infections (pneuthonia 4, bronchiectasis 4, acute bronchitis 2, and chronic bronchitis 1) were treated with oral RU 28965 in a daily dose of 300-400 mg for 4-24 days. Clinical efficacy was good in 5 cases, fair in 5 and poor in 1, with an overall clinical efficacy rate of 45.5%.Four strains of H. influenzae were isolated from sputum. Two strains were eradicated and the rest were unchanged after the treatment. Neither clinical side-effects nor abnormal laboratory findings were observed. 肺炎4例, 気管支拡張症感染4例, 急性気管支炎2例, および慢性気管支炎急性増悪の計11例の呼吸器感染症にマクロライド系抗生物質RU28965を投与し, 臨床的検討を行った。投与量は分2で1日300mgあるいは400mgで, 投与期間は4～24日であった。臨床効果は有効5例, やや有効5例, 無効1例で, 有効率は45.5%であった。本剤投与による副作用, 臨床検査値異常は認められなかった。
Author KABE, JUNZABURO
SATOH, TOSHINOBU
KOWADA, AKIKO
YOSHIMOTO, KEIKO
KUDO, KOICHIRO
Author_FL 小和田 暁子
佐藤 寿伸
工藤 宏一郎
可部 順三郎
吉本 恵子
Author_FL_xml – sequence: 1
  fullname: 工藤 宏一郎
– sequence: 2
  fullname: 佐藤 寿伸
– sequence: 3
  fullname: 小和田 暁子
– sequence: 4
  fullname: 吉本 恵子
– sequence: 5
  fullname: 可部 順三郎
Author_xml – sequence: 1
  fullname: SATOH, TOSHINOBU
  organization: Division of Pulmonary Diseases, National Medical Center Hospital
– sequence: 1
  fullname: KUDO, KOICHIRO
  organization: Division of Pulmonary Diseases, National Medical Center Hospital
– sequence: 1
  fullname: KABE, JUNZABURO
  organization: Division of Pulmonary Diseases, National Medical Center Hospital
– sequence: 1
  fullname: YOSHIMOTO, KEIKO
  organization: Division of Pulmonary Diseases, National Medical Center Hospital
– sequence: 1
  fullname: KOWADA, AKIKO
  organization: Division of Pulmonary Diseases, National Medical Center Hospital
BackLink https://cir.nii.ac.jp/crid/1390001206287379840$$DView record in CiNii
BookMark eNpdkE9PwkAQxTcGExH5Dj2YeLE4-5fdIyGgTRpqSjl4WrftVEqgNG098O0twYNymckveTN5792TQXWskJBnChNKmYSXbIuHY7fFxtUnaiSfcDVZf9f1Hg9YdcJyUDdkSLUWvtRGDMgQAIzPqZJ3ZNy2ZQpAKSim2ZA8RfEs9OKNx7RR0gtWXrxYvwfxLInijx6Xi3kSRKv1A7kt3L7F8e8ekc1ykczf_DB6Deaz0N8xITtfSJfy3AmGhXYSMM2FwtykUwc00w5kzlSPWVpkMlWFwd6ZA-CGGZ5LYfiIPF7-VmVps_I8KTd9AMrOjqd8arSAXvZ5ke3azn2hrZvy4JqTdU1XZnu01x1Zruy_jq4Q1J9T11is-A9VcGvP
ContentType Journal Article
Copyright Japanese Society of Chemotherapy
Copyright_xml – notice: Japanese Society of Chemotherapy
DBID RYH
DOI 10.11250/chemotherapy1953.36.Supplement4_306
DatabaseName CiNii Complete
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate 呼吸器感染症に対するRU 28965の臨床的検討
DocumentTitle_FL 呼吸器感染症に対するRU 28965の臨床的検討
EISSN 1884-5894
EndPage 310
ExternalDocumentID 130004196309
article_chemotherapy1953_36_Supplement4_36_Supplement4_306_article_char_en
GroupedDBID 53G
ADBBV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
DIK
JSF
JSH
KQ8
RJT
RZJ
ZOHVM
RYH
ID FETCH-LOGICAL-j245t-45ab3da42ef8a50ebd46ed9b7a01c8a05d26d9bcbfc5b6f9e009a0039293d5493
ISSN 0009-3165
IngestDate Thu Jun 26 23:05:55 EDT 2025
Wed Sep 03 06:30:12 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Issue Supplement4
Language English
Japanese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-j245t-45ab3da42ef8a50ebd46ed9b7a01c8a05d26d9bcbfc5b6f9e009a0039293d5493
OpenAccessLink https://www.jstage.jst.go.jp/article/chemotherapy1953/36/Supplement4/36_Supplement4_306/_article/-char/en
PageCount 5
ParticipantIDs nii_cinii_1390001206287379840
jstage_primary_article_chemotherapy1953_36_Supplement4_36_Supplement4_306_article_char_en
PublicationCentury 1900
PublicationDate 1988-00-00
PublicationDateYYYYMMDD 1988-01-01
PublicationDate_xml – year: 1988
  text: 1988-00-00
PublicationDecade 1980
PublicationTitle CHEMOTHERAPY
PublicationTitleAlternate Chemother.
PublicationTitle_FL ＣＨＥＭＯＴＨＥＲＡＰＹ
Chemother
PublicationYear 1988
Publisher Japanese Society of Chemotherapy
公益社団法人 日本化学療法学会
Publisher_xml – name: Japanese Society of Chemotherapy
– name: 公益社団法人 日本化学療法学会
References 1) BARLAM, T.; H. C.NEU: In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 25 (4): 529-531, 1984
2) 第35回日本化学療法学会総会, 新薬シンポジウムIV. RU 28965, 盛岡, 1987
References_xml – reference: 2) 第35回日本化学療法学会総会, 新薬シンポジウムIV. RU 28965, 盛岡, 1987
– reference: 1) BARLAM, T.; H. C.NEU: In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 25 (4): 529-531, 1984
SSID ssib001106282
ssj0000626693
ssib058492509
ssib005879733
ssib008506721
Score 1.1979051
Snippet We carried out a study on the clinical efficacy and safety of RU 28965. In total, eleven patients with respiratory infections (pneuthonia 4, bronchiectasis 4,...
SourceID nii
jstage
SourceType Publisher
StartPage 306
Title ORAL RU 28965 IN RESPIRATORY INFECTIONS
URI https://www.jstage.jst.go.jp/article/chemotherapy1953/36/Supplement4/36_Supplement4_306/_article/-char/en
https://cir.nii.ac.jp/crid/1390001206287379840
Volume 36
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX CHEMOTHERAPY, 1988/09/25, Vol.36(Supplement4), pp.306-310
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1884-5894
  dateEnd: 19941231
  omitProxy: true
  ssIdentifier: ssj0000626693
  issn: 0009-3165
  databaseCode: KQ8
  dateStart: 19530101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVBFR
  databaseName: Free Medical Journals - Free Access to All
  customDbUrl:
  eissn: 1884-5894
  dateEnd: 20041231
  omitProxy: true
  ssIdentifier: ssj0000626693
  issn: 0009-3165
  databaseCode: DIK
  dateStart: 19530101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELe6ISFeEAgQA4bygMTDSEkTx4kf09Ep2UQzZY208hLZTiK1EgVN3QN8J74jd3aWuIOHgeDFql2d08tdLz9f7g8hb1rBRMRU6NKJVC5tJSYrY5QFU1LUkrYm6_3jnKUlPb0ML0ejH1bU0vVWjtX33-aV_I1UYQ3kilmyfyDZflNYgM8gXxhBwjDeScZ5gfEN5REcZ1h4lM3x9c95ViSLvFjC9GSmI0QubACKJRDyRTorkvMexF4AQaoFl6P3Kp-WvRkuP-TaFOTZcZoVeb-eTHUU5Wk5_5RMy-GLJe4AFzBUs-wsH9wKE25a6xljDw9pbH7Zh43qsJDmc5cQ9m3HmnKw4abXw7gxBjSOqRvGpnHxjYU1JU46TdLdSrXrk1qGM_CY9QwOTKjrr-YdABsIRVk_B18DjgM2trat-s12Cml3YqpuU1cBq3aob009Vg2k4goUb4_c8yMANojBs7MBfU4wIdWqfhZHPLLQNBYHtKrRAfTjwA_vXYJAzRjve__hnb1P3t3w_f4OXAOMWsOhAqtF7G1WKwspLR6Rh90Rx0kMN4_JaC2ekLeoq05ROlpXnWzuWLrqDLr6lJQns8Vx6nZNOty1T8OtS0Mhg1pQv2ljEXqNrClrai4j4U1ULLyw9hlMlWxVKFnLG2BNYEY44Mw6pDx4RvY3XzbNc-JEcBSOedtg7jUNhBKwR8NU5LdeHfuT9oAsDXfVV1OJpfp3Ij0gh3DDKrXCEU5F2kOL4oyCiMfUe_Efr_2SPMB_oHHsvSL726vr5hCg7la-1gr2E_e0obc
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=ORAL+RU+28965+IN+RESPIRATORY+INFECTIONS&rft.jtitle=CHEMOTHERAPY&rft.au=SATOH%2C+TOSHINOBU&rft.au=KUDO%2C+KOICHIRO&rft.au=KABE%2C+JUNZABURO&rft.au=YOSHIMOTO%2C+KEIKO&rft.date=1988&rft.pub=Japanese+Society+of+Chemotherapy&rft.issn=0009-3165&rft.eissn=1884-5894&rft.volume=36&rft.issue=Supplement4&rft.spage=306&rft.epage=310&rft_id=info:doi/10.11250%2Fchemotherapy1953.36.Supplement4_306&rft.externalDocID=article_chemotherapy1953_36_Supplement4_36_Supplement4_306_article_char_en
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-3165&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-3165&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-3165&client=summon